Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Potential mechanisms for poor prognosis in CD5+ DLBCL

Key clinical point: Lenalidomide, BTK inhibitors, Bcl-2 inhibitors, and immune therapy, among others, present promising results in vitro.

Major finding: Potential mechanisms fall into two pathways: the CD5-mediated BCR-dependent pathway and the CD5-mediated BCR-independent pathway.

Study details: Review of the biology, mechanisms, and treatment approaches in de novo CD5+ DLBCL.

Disclosures: The study was supported by grants from the National Natural Science Foundation of China and the Natural Science Foundation of Jiangxi province. The authors reported having no disclosures.


Xu Y et al. Clinical Lymphoma Myeloma and Leukemia. 2020;